Professional Marketing briefs: August 2012

Share this article:
Professional Marketing briefs: August 2012
Professional Marketing briefs: August 2012

Lundbeck plans to lay off up to 600 employees that are part of its European operations. A spokesperson told MM&M that the 600 number is flexible—the company has to negotiate with local work councils, and won't have a definitive number until those talks end. Lundbeck said in a statement that the proposed layoffs will help the drugmaker mitigate price pressures of healthcare reform and generics and to weather “uncertainty regarding pricing and reimbursement in Europe.”

Pfizer announced it is spinning off its animal health business. The new company will be named Zoetis, which the company said means “pertaining to life.” The company said the business, which boasts more than 9,000 employees, pulled in sales of about $4.2 billion in 2011.

Johnson & Johnson's $19.7 billion purchase of Swiss device maker Synthes got FTC approval, having won the blessing of antitrust regulators in both the US and Europe. Approval required J&J to divest its DePuy Orthopedics Trauma business. The FTC's demands make it clear that the original deal would have created a near-monopoly in that market, giving J&J 70% of the US market for treating wrist fractures.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?